Article

COVID-19: No strong local response of the conjunctival immune system

Author(s):

Symptoms in the eye may not be substantial in patients with COVID-19.

COVID-19: No strong local response of the conjunctival immune system

Ophthalmic symptoms may not constitute a substantial element in the clinical picture of novel COVID-19 infection, according to investigators.

Polish investigators, led by Anna Niedźwiedź, MD, from the Department of General Pathology, Pomeranian Medical University, Szczecin, Poland, reported that the SARS-CoV-2 virus does not cause a strong local response of the conjunctival immune system, meaning that symptoms in the eye may not be substantial in patients with COVID-19.1

The investigators conducted a study in which they assessed the presence and duration of ocular symptoms during early-phase COVID-19 infections to determine the local immune response on the ocular surface.

The study was based on concerns by clinicians that the SARS-CoV-2 virus was transmitted via the tears and conjunctival secretions. In addition, some patients had conjunctivitis as the first symptom of COVID-19, which the authors explained may indicate that the ocular route could be a probable transmission path of SARS-CoV-2 to the rest of the human body.

The main outcome among the 180 study patients compared with 160 healthy age-matched controls was the occurrence of ophthalmologic manifestations at hospital admission and during the previous 7 days before admission. The investigators measured the tear film concentrations of tumor necrosis factor-α, interleukin-1b, -2, -4, -5, -6, -8, -10, -12 p70, granulocyte-macrophage colony-stimulating factor, and interferon-gamma.

Among the patients, 13% and 24%, respectively, exhibited at least one ocular symptom at admission and symptoms within the 7 days before hospital admission, which was significant compared with controls(p < 0.001). The patients complained significantly more often about ocular tearing (p = 0.04) and pain (p = 0.01) than controls.

Multivariate analysis showed that COVID-19 was a significant independent factor associated with higher levels of vascular endothelial growth factor and interleukin-10 tear film concentrations (p = 0.047 and p < 0.001, respectively) and significantly lower levels of interleukin-1β, interleukin-8, and granulocyte-macrophage colony-stimulating factor (p < 0.001; p = 0.004; and p = 0.0, respectively).

Based on the results, the investigators, “SARS-CoV-2 does not attract a strong local response of the conjunctival immune system; therefore, ophthalmic symptoms may not constitute a substantial element in the clinical picture of novel COVID-19 infection.”

Reference
  1. Niedźwiedź A, Kawa M, Pius-Sadowska E, et al. Evaluating ocular symptoms and tear film cytokine profiles in symptomatic COVID-19 patients. J Clin Med. 2022;11:2647; https://doi.org/10.3390/jcm11092647

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.